Form 4: BioMarin Executive Cristin Hubbard Reports Stock Option Grant and RSU Vesting

EVP, Chief Commercial Officer of BioMarin Pharmaceutical, Cristin Hubbard, reports acquisition of stock options and restricted stock units (RSUs) along with the disposal of some shares.

Summary

• On March 17, 2025, Cristin Hubbard, EVP, Chief Commercial Officer of BioMarin Pharmaceutical Inc., reported transactions involving the company's stock.
• Hubbard acquired 30,880 stock options with an exercise price of $71.55, vesting in installments starting March 17, 2026, and expiring on March 16, 2035.
• She also acquired 13,310 shares of common stock through restricted stock units (RSUs) granted on the same date.
• Additionally, Hubbard disposed of 32,700 shares of common stock.
• Following these transactions, Hubbard directly owns 30,880 derivative securities and 32,700 shares of common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document primarily reports transactions without providing explicit positive or negative commentary. The stock disposal could be seen as slightly negative, but without further context, it's difficult to assess the overall impact.

Positives

• The acquisition of stock options and RSUs by a key executive could be interpreted as a positive sign, indicating confidence in the company's future performance.

Negatives

• The disposal of 32,700 shares could be seen as a negative signal, although the reason for the disposal is not specified.

Risks

• The value of the stock options is dependent on the future performance of BioMarin's stock price, which is subject to market risks and company-specific factors.
• The vesting schedule of the stock options means that the executive's incentives are aligned with the long-term performance of the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants and RSU awards are common forms of executive compensation in the pharmaceutical industry.
• The vesting schedules and exercise prices are typically structured to align executive incentives with long-term shareholder value creation.
• Comparing the size and terms of these grants to those of peer companies (e.g., Vertex Pharmaceuticals, Amgen, Gilead Sciences) would provide a better understanding of BioMarin's compensation practices.

Stakeholder Impact

• Shareholders may be interested in the transactions of company insiders as an indicator of management's confidence in the company.
• Employees may view the stock option grants as a positive sign of the company's commitment to employee compensation.

Key Dates